Resources

2013 ∙ De la Hoz-Restrepo, F. Castañeda-Orjuela, C. Paternina, A. Alvis-Guzman, N.

Systematic review of incremental non-vaccine cost estimates used in cost-effectiveness analysis on the introduction of rotavirus and pneumococcal vaccines

2013 ∙ Bahia, L. Toscano, C. M. Takemoto, M. Auraujo, V.

Systematic review of pneumococcal disease costs and productivity loss studies in Latin America and the Caribbean

2013 ∙ Davis, S. Feikin, D. Johnson, H. L.

The effect of Haemophilus influenzae type B and pneumococcal conjugate vaccines on childhood meningitis mortality: A systematic review

2013 ∙ Dolan, G. P. Harris, R. C. Clarkson, M. Sokal, R. Morgan, G. Mukaigawara, M. Horiuchi, H. Hale, R. Stormont, L. Béchard-Evans, L. Chao, Y. S. Eremin, S. Martins, S. Tam, J. Peñalver, J. Zanuzadana, A. Nguyen-Van-Tam, J. S.

Vaccination of healthcare workers to protect patients at increased risk of acute respiratory disease: Summary of a systematic review

2013 ∙ Health Council of the Netherlands

Vaccination of infants against pneumococcal infections (3) – 27 November 2013

2013 ∙ JCVI

JCVI statement on the wider use of pneumococcal conjugate vaccines in the UK

2013 ∙ ACIP

Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Children Aged 6–18 Years with Immunocompromising Conditions

2012 ∙ Cadeddu, C. De Waure, C. Gualano, M. R. Di Nardo, F. Ricciardi, W.

23-valent pneumococcal polysaccharide vaccine (PPV23) for the prevention of invasive pneumococcal diseases (IPDs) in the elderly: Is it really effective?

2012 ∙ Agarwal, N. Ollington, K. Kaneshiro, M. Frenck, R. Melmed, G. Y.

306 results found